Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Genome Medicine|December 30, 2018
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage responsePaola Francica, Sven Rottenberg
Frontiers in Genetics|March 7, 2022
Meiotic Genes and DNA Double Strand Break Repair in CancerLea Lingg, Sven Rottenberg, Paola Francica
Biochemical Pharmacology|August 31, 2016
Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancerPaola Francica, Daniel M Aebersold, Michaela Medová
Advances in Anatomic Pathology|November 27, 2023
DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic Prostate CancerDilara Akhoundova, Paola Francica, Sven Rottenberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 20, 2024
Docetaxel response in BRCA1,p53-deficient mammary tumor cells is affected by Huntingtin and BAP1Martín González-Fernández, Carmen Perry, Nora Merete Gerhards, et al.
Oncotarget|September 8, 2016
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenograftsElena Andreucci, Paola Francica, Antony Fearns, et al.
FEBS Letters|January 21, 2014
Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulationDominic Leiser, Benoît Pochon, Wieslawa Blank-Liss, et al.
Molecular Cancer|May 24, 2017
PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer modelsLluís Nisa, Pascal Häfliger, Michaela Poliaková, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2016
Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric CancerPaola Francica, Lluís Nisa, Daniel M Aebersold, et al.
Molecular Cancer Therapeutics|September 25, 2013
The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variantsMichaela Medová, Benoît Pochon, Bruno Streit, et al.
Pageof 2